Extending the reach of expert amyloidosis care: A feasibility study exploring the staged implementation of a UK amyloidosis network.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: The College Country of Publication: England NLM ID: 101092853 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4893 (Electronic) Linking ISSN: 14702118 NLM ISO Abbreviation: Clin Med (Lond) Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : The College, c2001-
    • Subject Terms:
      Prealbumin* ; Amyloidosis*; Humans ; Male ; Aged ; Feasibility Studies ; Ambulatory Care Facilities ; London
    • Abstract:
      There has been an exponential increase in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CA). In response, the Midlands Amyloidosis Service was launched with the aim of providing patients with a timely diagnosis, remote expertise from the National Amyloidosis Centre and access to emerging transthyretin (TTR)-directed therapies. This was a descriptive study of a pilot hub-and-spoke model of delivering specialist amyloidosis care. Patients with suspected amyloidosis were referred from the wider Midlands region, and seen in a consultant-led multidisciplinary clinic. The diagnosis of ATTR-CA was established according to either the validated non-biopsy criteria or histological confirmation of ATTR deposits with imaging evidence of amyloid. Study endpoints were the volume of service provision and the time to diagnosis from the receipt of referral. Patients (n=173, age 75±2 years; male 72 %) were referred between 2019 and 2021. Eighty patients (46 %) were found to have cardiac amyloidosis, of whom 68 (85 %) had ATTR-CA. The median time from referral to diagnosis was 43 days. By removing the need for patients to travel to London, an average of 187 patient-miles was saved. Fifteen (9 %) patients with wild-type ATTR-CA received tafamidis under the Early Access to Medicine scheme; 10 (6 %) were enrolled into phase 3 clinical trials of RNA interference or antisense oligonucleotide therapies. Our results suggest that implementing a UK amyloidosis network appears feasible and would enhance equity of access to specialised amyloidosis healthcare for the increasing numbers of older patients found to have ATTR-CA.
      Competing Interests: Conflicts of interest WEM has received advisory board fees from Alnylam, Ionis Pharmaceuticals (formerly Akcea) and Pfizer.
      (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • References:
      Circulation. 2016 Jun 14;133(24):2404-12. (PMID: 27143678)
      ESC Heart Fail. 2020 Oct;7(5):2418-2430. (PMID: 32588554)
      Cardiol Ther. 2019 Dec;8(2):297-316. (PMID: 31376091)
      Front Cardiovasc Med. 2021 Dec 10;8:751293. (PMID: 34957240)
      Future Healthc J. 2022 Mar;9(1):28-33. (PMID: 35372776)
      J Am Coll Cardiol. 2020 Jul 7;76(1):93-95. (PMID: 32616166)
      Eur Heart J. 2019 Jun 1;40(21):1661-1664. (PMID: 31152551)
      Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30-s35. (PMID: 29700090)
      J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. (PMID: 25559473)
      JACC Clin Electrophysiol. 2020 Sep;6(9):1118-1127. (PMID: 32972546)
      Circ Heart Fail. 2016 Jun;9(6):e002558. (PMID: 27188913)
      Rev Esp Cardiol (Engl Ed). 2021 Feb;74(2):149-158. (PMID: 32317158)
      Hum Genet. 2015 Jan;134(1):111-21. (PMID: 25367359)
      Circulation. 2015 Oct 20;132(16):1570-9. (PMID: 26362631)
      Front Cardiovasc Med. 2022 May 17;9:863179. (PMID: 35656395)
      ESC Heart Fail. 2018 Oct;5(5):772-779. (PMID: 29916559)
      Echo Res Pract. 2023 Aug 31;10(1):13. (PMID: 37653443)
      Circ Heart Fail. 2016 Sep;9(9):. (PMID: 27618855)
      Adv Ther. 2022 Jun;39(6):2292-2301. (PMID: 35419651)
      Eur Heart J. 2021 Apr 21;42(16):1554-1568. (PMID: 33825853)
      Front Neurol. 2022 Apr 08;13:844595. (PMID: 35463150)
      Br J Haematol. 2013 May;161(4):525-32. (PMID: 23480608)
      Circulation. 2019 Jul 2;140(1):16-26. (PMID: 31109193)
      Cardiol Ther. 2021 Jun;10(1):141-159. (PMID: 33877591)
      J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84. (PMID: 16168294)
      PLoS Med. 2007 Oct 16;4(10):e297. (PMID: 17941715)
      Eur Heart J. 2018 Aug 7;39(30):2799-2806. (PMID: 29048471)
    • Contributed Indexing:
      Keywords: Amyloidosis; Screening; Transthyretin amyloid cardiomyopathy
    • Accession Number:
      0 (Prealbumin)
    • Publication Date:
      Date Created: 20240220 Date Completed: 20240304 Latest Revision: 20240425
    • Publication Date:
      20240425
    • Accession Number:
      PMC10907332
    • Accession Number:
      10.1016/j.clinme.2023.100004
    • Accession Number:
      38377730